Samphire Neuroscience Revolutionizes Menstrual Health with Nettle Wearable

Samphire Neuroscience, a London-based startup, has raised a whopping $2.3 million in Pre-Seed funding to launch Nettle, a groundbreaking neurostimulation wearable designed to target PMS and menstrual pain. This innovative device aims to provide effective relief without the adverse side effects or sacrifices often associated with traditional medical interventions. With over 90% of women experiencing premenstrual symptoms and up to 91% suffering from period cramps, the need for better menstrual health solutions is undeniable. Samphire Neuroscience, co-founded by neuroscientist Emilė Radytė and lawyer Alex Cook, is on a mission to offer safe and tailored options for those dealing with menstrual health issues. Nettle, the company's first solution, uses transcranial direct current stimulation (tDCS) to modulate neuronal activity in the prefrontal and motor cortex, providing a holistic approach to managing chronic pain and mood symptoms. By targeting the brain-uterus connection, Nettle aims to address the complex interplay between hormone levels, brain activity, and menstrual cycle phases. This groundbreaking technology has already been proven to be twice as effective as the most common antidepressants, setting a new standard for menstrual health care. The funding round, which saw contributions from notable venture firms and angel investors, underscores the growing recognition of the importance of women's health and the potential for brain-based therapies to revolutionize the field. Samphire Neuroscience's innovative approach and commitment to empowering women to take control of their health signal a new era in menstrual health care, where effective, safe, and tailored solutions are within reach.